Key Inclusion Criteria:

          -  Patients must have a site of disease amenable to biopsy, and be a candidate for tumor
             biopsy according to the treating institution's guidelines. Patients must be willing to
             undergo a new tumor biopsy at baseline and during on study therapy. Exceptions may be
             considered after documented discussion with Novartis.

          -  All patients must have a BRAF V600 mutation confirmed by local assessment.

          -  Patients with unresectable advanced/metastatic BRAF V600 cancer of the colon or rectum
             with measurable disease as determined by RECIST v1.1

          -  Patients must have documented disease progression following, or are intolerant to, 1
             or 2 lines of chemotherapy for advanced/metastatic disease

        Key Exclusion Criteria:

          -  Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy, or in-situ cervical cancer, or
             other tumors that will not affect life expectancy

          -  Impairment of gastrointestinal function or gastrointestinal disease that may
             signficantly alter the absorption of study drugs

          -  History of or current evidence/risk of retinal verin occlusion or serous retinopathy

          -  History of or current interstitial lung disease or non-infectious pneumonitis

          -  Patients with a known history of testing positive for HIV

          -  Clinically significant cardiac disease at screening

          -  Any medical condition that would, in the investigator's judgment, prevent the
             patient's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures.

          -  Pregnant or lactating women